begin
brought
us
inform
novel
coronaviru
emerg
china
rapid
research
result
character
pathogen
appear
member
sarslik
cluster
commonli
seen
bat
despit
global
local
effort
viru
escap
healthcar
measur
rapidli
spread
china
later
global
offici
caus
pandem
global
crisi
march
present
differ
scenario
written
contain
viru
develop
novel
anticoronavir
highli
pathogen
coronavirus
remain
major
challeng
describ
antivir
activ
previous
develop
us
htcc
compound
n
chitosan
chlorid
may
use
potenti
inhibitor
current
circul
highli
pathogen
coronavirus
merscov
biorxiv
preprint
pneumocyt
human
airway
hijack
angiotensinconvert
enzym
enter
cell
similarli
sarscov
merscov
relat
togeth
bat
virus
form
separ
merbecoviru
subgenu
bat
believ
serv
origin
reservoir
also
case
camel
identifi
intermedi
host
viru
never
fulli
cross
speci
border
humantohuman
transmiss
limit
almost
case
associ
animaltohuman
transmiss
entri
receptor
merscov
dipeptidyl
peptidas
human
merscov
caus
respiratori
ill
authorfund
right
reserv
reus
allow
without
permiss
coronavirus
mainli
caus
respiratori
enter
diseas
human
mammal
bird
howev
speci
caus
sever
condit
hepat
periton
neurolog
diseas
seven
coronavirus
infect
human
four
human
pangolin
suggest
viru
associ
respiratori
ill
proport
case
sever
mortal
rate
vari
locat
present
estim
reach
global
viru
infect
primarili
ciliat
cell
type
ii
sever
vari
asymptomat
potenti
fatal
acut
respiratori
distress
date
merscov
infect
confirm
countri
case
mortal
rate
current
vaccin
drug
proven
efficaci
treat
coronaviru
infect
treatment
limit
support
care
howev
rang
therapeut
consequ
broadspectrum
antivir
essenti
longterm
perspect
dissect
mechan
htcc
antivir
activ
show
polym
interact
coronavir
spike
protein
block
interact
cellular
receptor
analyz
htcc
activ
merscov
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
vitro
use
permiss
cell
line
ex
vivo
use
model
human
airway
epithelium
hae
studi
show
replic
virus
effici
hamper
overal
data
show
htcc
polym
potent
broadspectrum
anticoronavir
may
promis
drug
candid
merscov
previous
show
htcc
differ
degre
substitut
dss
studi
merscov
use
vero
cell
reveal
htcc
variant
inhibit
viru
replic
similar
extent
decreas
viral
yield
toxic
concentr
figur
c
inhibit
infect
vero
cell
even
pronounc
htcc
variant
inhibit
viru
replic
time
nontox
concentr
figur
c
case
arbitrarili
select
studi
merscov
select
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
next
dosedepend
test
htcc
inhibitori
activ
select
polym
verifi
three
differ
concentr
obtain
data
shown
figur
base
data
obtain
basic
paramet
calcul
present
tabl
paramet
observ
appear
favor
si
also
worth
note
htcc
previous
administ
inhal
rat
advers
reaction
observ
studi
htcc
use
carrier
activ
substanc
report
promis
local
sustain
inhal
therapi
pulmonari
diseas
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
vero
cell
constitut
conveni
model
antivir
research
utmost
import
verifi
whether
result
obtain
bias
due
artifici
system
use
especi
import
compound
activ
base
electrostat
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
previou
research
show
htccmediat
inhibit
coronavir
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
next
verifi
whether
mechan
action
highli
pathogen
betacoronavirus
similar
observ
alphacoronavirus
base
lock
interact
viru
entri
receptor
analyz
merscov
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
take
togeth
show
previous
develop
describ
polymer
htcc
anticoronavir
compound
base
chitosan
abl
effici
inhibit
infect
emerg
coronavirus
believ
htcc
finetun
target
coronaviru
interact
specif
virus
belong
coronavirida
famili
activ
compound
htcc
prepar
manner
previous
describ
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sequenc
verifi
gift
xingchuan
huang
pspax
addgen
plasmid
addgen
plasmid
gift
didier
trono
vector
addgen
plasmid
gift
bori
feh
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cell
viabil
assay
hae
cultur
prepar
describ
cell
viabil
assay
perform
tpp
expos
merscov
mock
per
ml
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
presenc
test
polym
control
medium
follow
h
incub
unbound
virion
remov
wash
pb
fresh
medium
contain
dissolv
respect
polym
ad
well
sampl
cell
cultur
supernat
collect
day
pi
analyz
use
rtqpcr
ex
vivo
studi
fulli
differenti
human
airway
epithelium
hae
cultur
expos
test
polym
control
pb
min
follow
inocul
copyright
holder
preprint
peerreview
scientif
volum
imag
bv
netherland
process
use
imagej
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
nation
institut
health
bethesda
md
usa
time
studi
antibodi
specif
avail
us
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
